Allergy

Dr. Kidon spoke in this interview segment regarding a recent immunotherapy product she and her team have been focused on for patients with peanut allergies.

This interview with Dr. Kidon featured a discussion regarding Kidon’s current peanut allergy research and views on recent developments in the field.

This new data on younger acute sinusitis patients may indicate the value of testing for specific bacteria at the time of presentation in order to lower the use of antibiotics for this condition.

This new research examined trends among adults with severe and recurrent anaphylaxis, and identified several major risk factors.

This new research is the first to examine the use of the iMAP milk ladder in primary care settings for younger patients with IgE-mediated cow’s milk protein allergy.

These new findings may lead to a more accessible and rigorous approach to diagnosis, with a possibility of reduction of over-diagnosis.

New data indicates associations between conditions for pregnant mothers and offspring, though a connection to offspring food allergy was not evident in this research.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.

New data led to positive results for the simple-to-use PEN-FAST tool, allowing its use among allergists and even primary care physicians in cases in which access to allergists is limited.

This data indicates that public health officials may need to implement measures to both help prevent and detect domestic violence in order to reduce the associated effects.

Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.

Climate and vegetation changes in China may have led to increases in sensitivity to weed pollens and molds over the past 5 years, though the number one aeroallergen remains to be house dust mites.

Adaptation of penicillin allergy clinical decision tool PEN-FAST showed strong performance, indicating the potential utility of the tool for identifying patients with low-risk allergy phenotypes who may safely undergo direct oral challenges.

These findings are relevant given that if labels are incorrectly identified, those with allergies may be at risk of severe reactions or receive suboptimal treatment.

New research has led to the development of an algorithm designed to help improve detection of allergic reactions to antibiotics, given that antibiotics are among the most common medication adverse event causes.

Allergic disease and asthma have become distinctly linked among a significant proportion of patients. A pulmonologist and allergist review diagnostics, guidelines and research relevant to the interplay.

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

There have been long stretches of time between the innovation of epinephrine delivery in the allergy space.

It was announced by ARS Pharmaceuticals, Inc., that a US Food and Drug Administration Drug Advisory Committee voted in favor of a new intranasal epinephrine treatment for severe allergic reactions.

Bryn Pharma is planning to submit the New Drug Application for Utuly this year and expects to receive approval early next year.

Data presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting show promise for Utuly, a novel intranasal epinephrine spray for treating anaphylaxis.

IgE-mediated children with cow’s milk allergies switching from amino acid-based formula to a new formula showed strong tolerance and better acquisition of immune tolerance, suggesting other studies combining treatments may be useful.

In this interview segment, Fleischer further described some of the key points about the peanut immunotherapy patch, DBV712, and the product’s phase 3 VITESSE trial.